Key Points
- CEO Steven Chapman sold 1,273 Natera shares for approximately $526,144 at an average price of $413.31 under a pre-arranged Rule 10b5-1 plan, reducing his stake by 1.3% to 96,926 shares.
- Natera shares opened at $425.64 and were up 3.7%, near their 12-month high of $427.47. The company’s latest quarterly revenue rose 37.7% year over year to $752.75 million, while its adjusted loss of $0.47 per share slightly beat analyst expectations.
- Analysts maintain a “Moderate Buy” consensus with an average price target of $341.55, while institutional investors own 99.90% of the stock.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Chapman sold 1,273 shares of Natera stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $413.31, for a total value of $526,143.63. Following the completion of the transaction, the chief executive officer owned 96,926 shares of the company's stock, valued at approximately $40,060,485.06. This represents a 1.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Steven Leonard Chapman also recently made the following trade(s):
- On Tuesday, September 1st, Steven Chapman sold 1,698 shares of Natera stock. The stock was sold at an average price of $320.99, for a total transaction of $545,041.02.
- On Monday, August 3rd, Steven Chapman sold 3,076 shares of Natera stock. The shares were sold at an average price of $266.39, for a total transaction of $819,415.64.
- On Tuesday, July 28th, Steven Chapman sold 3,580 shares of Natera stock. The stock was sold at an average price of $254.07, for a total value of $909,570.60.
- On Monday, July 27th, Steven Chapman sold 2,190 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $570,473.10.
Natera Trading Up 3.7%
Shares of NASDAQ NTRA opened at $425.64 on Tuesday. The stock has a market capitalization of $61.35 billion, a PE ratio of -312.97 and a beta of 1.50. The stock's fifty day simple moving average is $335.75 and its two-hundred day simple moving average is $263.06. Natera, Inc. has a 12-month low of $167.21 and a 12-month high of $427.47.
Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The firm had revenue of $752.75 million during the quarter, compared to analysts' expectations of $661.24 million. During the same period in the prior year, the business posted ($0.74) EPS. The firm's quarterly revenue was up 37.7% on a year-over-year basis. On average, equities analysts predict that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Natera
Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Natera during the second quarter worth about $2,962,770,000. JPMorgan Chase & Co. boosted its position in Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock worth $2,944,800,000 after purchasing an additional 1,225,420 shares in the last quarter. Castle Hook Partners LP grew its stake in shares of Natera by 24.1% during the 4th quarter. Castle Hook Partners LP now owns 2,167,869 shares of the medical research company's stock worth $496,637,000 after purchasing an additional 420,621 shares during the period. Capital World Investors increased its holdings in shares of Natera by 1.4% during the 4th quarter. Capital World Investors now owns 1,433,094 shares of the medical research company's stock valued at $328,308,000 after purchasing an additional 20,371 shares in the last quarter. Finally, Lord Abbett & CO. LLC lifted its stake in shares of Natera by 10.0% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,219,045 shares of the medical research company's stock valued at $279,271,000 after purchasing an additional 110,715 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on NTRA shares. Evercore restated an "outperform" rating and issued a $300.00 target price on shares of Natera in a research note on Monday, July 6th. Sanford C. Bernstein began coverage on Natera in a research note on Friday, June 26th. They set an "outperform" rating and a $310.00 price target on the stock. Guggenheim boosted their target price on shares of Natera from $360.00 to $475.00 and gave the stock a "buy" rating in a research report on Thursday. Piper Sandler raised their price target on shares of Natera from $249.00 to $363.50 and gave the stock an "overweight" rating in a report on Wednesday, August 12th. Finally, Barclays reissued an "overweight" rating and set a $340.00 price objective on shares of Natera in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $341.55.
Check Out Our Latest Stock Report on NTRA
About Natera
(
Get Free Report)
Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.
Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
